tozasertib
Small moleculeexperimental
Tozasertib (VX-680) is an aurora inhibitor. — Wikipedia
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT00099346)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 1
- Leukemia · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
Serine/threonine-protein kinase Aurora inhibitor
Pan-Aurora kinase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1- Mol. weight
- 464.6 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTozasertib ↗
- ChEMBLCHEMBL572878 ↗
Also known as
- cyclopropane carboxylic acid(4-(4-(4-methylpiperazin-1-yl)-6-(5-methyl-2h-pyrazol-3-ylamino)pyrimidin-2-ylsulfanyl)phenyl)amide
- mk-045
- mk-045
- mk0457
- mk0457
- mk-0457
- mk-0457
- mk-0457
- mk-0457
- tozasertib
- tozasertib
- tozasertib
- ve 465
- ve-465
- vx-68
- vx-68
- vx680
- vx-680
- vx-680
- vx-680
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00500006 | Phase 1 | Oct 1, 2007 | Merck |
| NCT00405054 | Phase 2 | Dec 1, 2006 | Merck |
| NCT00290550 | Phase 2 | Jun 1, 2006 | Merck |
| NCT00111683 | Phase 1 | Jun 1, 2005 | Merck |
| NCT02532868 | Phase 1 | May 1, 2005 | Merck |
| NCT00099346 | Phase 1 | Jan 1, 2005 | Merck |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 6 | 6 | 2 | 2005 |
1 organizations
Page 1 / 1